Type 2 diabetes management may be entering a new era as researchers demonstrate that combining two distinct hormone pathways produces superior glycemic control compared to single-agent therapy. This approach could reshape treatment for millions who struggle with inadequate blood sugar control despite lifestyle modifications.
The REIMAGINE 1 trial tested CagriSema, a weekly injection combining cagrilintide (an amylin receptor agonist) with semaglutide (a GLP-1 receptor agonist). Over 40 weeks, 673 adults with poorly controlled type 2 diabetes received either the combination therapy at two dose levels or matching placebos. The higher-dose combination (2.4 mg each compound) reduced HbA1c levels by 2.3 percentage points compared to placebo, while the lower dose achieved a 2.0 percentage point reduction. Both doses significantly outperformed placebo controls in this double-blind, placebo-controlled phase 3a study.
This dual-hormone strategy represents a sophisticated approach to diabetes management, targeting complementary metabolic pathways simultaneously. Amylin and GLP-1 receptors regulate glucose homeostasis through different mechanisms—amylin slows gastric emptying and suppresses glucagon, while GLP-1 enhances insulin secretion and reduces appetite. The combination's effectiveness suggests that multi-pathway intervention may be necessary for optimal diabetes control in treatment-resistant patients. However, the 40-week timeframe limits assessment of long-term durability and safety. Given semaglutide's known cardiovascular benefits, the addition of cagrilintide raises questions about whether this combination maintains or enhances those protective effects—a critical consideration for comprehensive diabetes care that extends beyond glucose control.